Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Juli 2025 07:00 ET | Quelle: Bonus Biogroup

Bonus Biogroup Appoints Renowned Cell Therapy Leader, Professor Edwin M. Horwitz, MD, PhD, to its Advisory Board

HAIFA, Israel, July 14, 2025 (GLOBE NEWSWIRE) -- Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stem cells (MSC) to develop...
20. Februar 2025 08:00 ET | Quelle: Bonus Biogroup

Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress

The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute respiratory distress syndrome (ARDS) MesenCure's market potential...
22. August 2021 04:20 ET | Quelle: Bonus BioGroup

Bonus BioGroup Receives Approval to Expand Phase-II Clinical Trials for its COVID-19 Treatment to Medical Centers Across Israel

TEL AVIV, ISRAEL, Aug. 22, 2021 (GLOBE NEWSWIRE) -- Bonus BioGroup LTD or "the Company" (BONS.TA), an Israeli clinical-stage biotechnology company, has received official approval from the Israeli...